B
9.50
-0.02 (-0.21%)
| 前收盘价格 | 9.52 |
| 收盘价格 | 9.60 |
| 成交量 | 3,588,350 |
| 平均成交量 (3个月) | 5,380,244 |
| 市值 | 2,382,605,824 |
| 市盈率 (P/E TTM) | 7.85 |
| 预期市盈率 (P/E Forward) | 109.89 |
| 价格/销量 (P/S) | 2.19 |
| 52周波幅 | |
| 利润日期 | 6 May 2026 |
| 营业毛利率 | -10.62% |
| 营业利益率 (TTM) | 14.59% |
| 稀释每股收益 (EPS TTM) | -0.260 |
| 季度收入增长率 (YOY) | 56.90% |
| 流动比率 (MRQ) | 2.93 |
| 营业现金流 (OCF TTM) | -25.85 M |
| 杠杆自由现金流 (LFCF TTM) | 42.90 M |
| 资产报酬率 (ROA TTM) | 4.54% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 看涨 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 看涨 | |
| 股票 | BioCryst Pharmaceuticals, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
-0.5
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.50 |
|
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.20% |
| 机构持股比例 | 87.44% |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 05 Feb 2026 | 公告 | BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 |
| 05 Feb 2026 | 公告 | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合